Ashley Adamson1, Silas A Buck2, Zachary Freyberg2,3, Briana R De Miranda4. 1. Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1719 6th Ave South, CIRC 560, Birmingham, AL, 35294, USA. 2. Center for Neuroscience, Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA. 4. Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, 1719 6th Ave South, CIRC 560, Birmingham, AL, 35294, USA. BrianaDeMiranda@uabmc.edu.
Abstract
PURPOSE OF REVIEW: Sex dimorphism in Parkinson's disease (PD) is an ostensible feature of the neurological disorder, particularly as men are 1.5-2 times more likely to develop PD than women. Clinical features of the disease, such as presentation at onset, most prevalent symptoms, and response to treatment, are also affected by sex. Despite these well-known sex differences in PD risk and phenotype, the mechanisms that impart sex dimorphisms in PD remain poorly understood. RECENT FINDINGS: As PD incidence is influenced by environmental factors, an intriguing pattern has recently emerged in research studies suggesting a male-specific vulnerability to dopaminergic neurodegeneration caused by neurotoxicant exposure, with relative protection in females. These new experimental data have uncovered potential mechanisms that provide clues to the source of sex differences in dopaminergic neurodegeneration and other PD pathology such as alpha-synuclein toxicity. In this review, we discuss the emerging evidence of increased male sensitivity to neurodegeneration from environmental exposures. We examine mechanisms underlying dopaminergic neurodegeneration and PD-related pathologies with evidence supporting the roles of estrogen, SRY expression, the vesicular glutamate transporter VGLUT2, and the microbiome as prospective catalysts for male vulnerability. We also highlight the importance of including sex as a biological variable, particularly when evaluating dopaminergic neurotoxicity in the context of PD.
PURPOSE OF REVIEW: Sex dimorphism in Parkinson's disease (PD) is an ostensible feature of the neurological disorder, particularly as men are 1.5-2 times more likely to develop PD than women. Clinical features of the disease, such as presentation at onset, most prevalent symptoms, and response to treatment, are also affected by sex. Despite these well-known sex differences in PD risk and phenotype, the mechanisms that impart sex dimorphisms in PD remain poorly understood. RECENT FINDINGS: As PD incidence is influenced by environmental factors, an intriguing pattern has recently emerged in research studies suggesting a male-specific vulnerability to dopaminergic neurodegeneration caused by neurotoxicant exposure, with relative protection in females. These new experimental data have uncovered potential mechanisms that provide clues to the source of sex differences in dopaminergic neurodegeneration and other PD pathology such as alpha-synuclein toxicity. In this review, we discuss the emerging evidence of increased male sensitivity to neurodegeneration from environmental exposures. We examine mechanisms underlying dopaminergic neurodegeneration and PD-related pathologies with evidence supporting the roles of estrogen, SRY expression, the vesicular glutamate transporter VGLUT2, and the microbiome as prospective catalysts for male vulnerability. We also highlight the importance of including sex as a biological variable, particularly when evaluating dopaminergic neurotoxicity in the context of PD.
Authors: Charlotte A Haaxma; Bastiaan R Bloem; George F Borm; Wim J G Oyen; Klaus L Leenders; Silvia Eshuis; Jan Booij; Dean E Dluzen; Martin W I M Horstink Journal: J Neurol Neurosurg Psychiatry Date: 2006-11-10 Impact factor: 10.154
Authors: Caroline M Tanner; G Webster Ross; Sarah A Jewell; Robert A Hauser; Joseph Jankovic; Stewart A Factor; Susan Bressman; Amanda Deligtisch; Connie Marras; Kelly E Lyons; Grace S Bhudhikanok; Diana F Roucoux; Cheryl Meng; Robert D Abbott; J William Langston Journal: Arch Neurol Date: 2009-09
Authors: Juan Camilo Jurado-Coronel; Ricardo Cabezas; Marco Fidel Ávila Rodríguez; Valentina Echeverria; Luis Miguel García-Segura; George E Barreto Journal: Front Neuroendocrinol Date: 2017-09-30 Impact factor: 8.606
Authors: Silas A Buck; Thomas Steinkellner; Despoina Aslanoglou; Michael Villeneuve; Sai H Bhatte; Victoria C Childers; Sophie A Rubin; Briana R De Miranda; Emma I O'Leary; Elizabeth G Neureiter; Keri J Fogle; Michael J Palladino; Ryan W Logan; Jill R Glausier; Kenneth N Fish; David A Lewis; J Timothy Greenamyre; Brian D McCabe; Claire E J Cheetham; Thomas S Hnasko; Zachary Freyberg Journal: Aging Cell Date: 2021-04-28 Impact factor: 11.005